The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation

BACKGROUND: Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patients is docetaxel-resistance. Defining the mechanisms of resistance so as to info...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundon, D. J., Boland, A., Prencipe, M., Hurley, G., O’Neill, A, Kay, E., Aherne, S. T., Doolan, P., Madden, S. F., Clynes, M., Morrissey, C., Fitzpatrick, J. M., Watson, R. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333466/
https://www.ncbi.nlm.nih.gov/pubmed/28249598
http://dx.doi.org/10.1186/s12885-017-3100-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333466/
https://www.ncbi.nlm.nih.gov/pubmed/28249598
http://dx.doi.org/10.1186/s12885-017-3100-4

Ejemplares similares